開拓藥業(09939.HK)ALK-1單抗聯合療法二期試驗完成美國首例患者給藥
開拓藥業(09939.HK)公佈,旗下產品ALK-1單抗(GT90001)聯合Nivolumab治療晚期肝細胞癌的全球多中心II期臨牀試驗,近日已完成美國首例患者給藥。
此前在臺灣進行的ALK-1單抗(GT90001)聯合Nivolumab治療晚期肝細胞癌二期臨牀試驗,初步數據已於今年1月舉行的美國臨牀腫瘤學會胃腸道腫瘤研討會上發佈,初步數據顯示聯合療法的療效令人鼓舞且安全性良好,客觀緩解率(ORR)達到40%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.